News

NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), achieves significant levels in the lungs and lowers the production of molecules that promote scarring, according to preclinical studies involving rats, the company announced. “We’re delighted with the positive readout of this data so far and it further…

Researchers have now compiled the most comprehensive molecular atlas, or roadmap, to date of healthy human lungs and their early development, leading to the identification of nearly 9,000 proteins whose production changes with age. The data, open to the public through an online platform called LungMAP, are expected to help…

LYT-100 (deupirfenidone), an experimental oral therapy containing a similar active ingredient to Esbriet, was well-tolerated at all tested doses — and did not reach the maximum tolerated dose or MTD — in a Phase 1 trial conducted in healthy volunteers. PureTech Health, which is developing LYT-100 for…

The American Thoracic Society (ATS) has premiered a docuseries called “Helping the World to Breathe,” showcasing the society’s commitment to advancing care for people with lung diseases. Over 16 episodes, the series highlights stories from clinicians, researchers, and patients collaborating to advance care. For example, scientists and patients at…

The National Institutes of Health (NIH) has awarded a grant to support research into immune mechanisms that could allow for the reversal of fibrosis, or tissue scarring, in idiopathic pulmonary fibrosis (IPF). The $469,034 award went to Narendiran Rajasekaran, PhD, and Archana Varadaraj, PhD, both of whom are assistant…

Scientists have developed a new lab-grown three-dimension (3D) microtissue model that replicates the key features of the idiopathic pulmonary fibrosis (IPF) microenvironment better than other cellular and animal models, and that enables more robust screening of potential therapies. When the model was generated using lung cells collected from IPF…

Reviva Pharmaceuticals is planning to seek the U.S. Food and Drug Administration’s (FDA) permission to begin Phase 2 clinical trials testing its investigational therapy brilaroxazine in people with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). “We … expect to begin regulatory submissions to the FDA…

An inhalable therapeutic is being developed using pressure-treated yeast beta-glucan for people with COVID-19 as well as other severe lung diseases, including idiopathic pulmonary fibrosis (IPF). Beta-glucans are fiber compounds that are naturally found in the cell walls of grains, bacteria, and fungi, such as yeast. Ceapro, a biotechnology…

The Microbiome Therapeutics Innovation Group (MTIG), a coalition of companies working to develop U.S. Food and Drug Administration (FDA)-microbiome-based therapies, announced the addition of Alveolus Bio to its group. Alveolus has more than a decade of research into neutrophilic inflammation — an asthmatic inflammation driven by specific white…

Alterations in lactic acid metabolism — part of the process that allows the body to produce energy in the absence of oxygen — were found in lung tissues collected from patients with idiopathic pulmonary fibrosis (IPF), a recent study reported. These findings suggest that lactic acid metabolism may be…